Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.

@article{Zeidan2017HypomethylatingAT,
  title={Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population-based study.},
  author={Amer M Zeidan and Xin Hu and Jessica B. Long and Rong Wang and Xiaomei Ma and Nikolai Podoltsev and Scott F Huntington and Steven D Gore and Amy J Davidoff},
  journal={Cancer},
  year={2017},
  volume={123 19},
  pages={3754-3762}
}
BACKGROUND Despite the approval of azacitidine in 2004 and the approval of decitabine in 2006 in the United States for chronic myelomonocytic leukemia (CMML), the overall survival (OS) benefit with hypomethylating agent (HMA) therapy is unclear. METHODS Older adults (age ≥ 66 years) who had been diagnosed with CMML from 2001 to 2011 were selected from the Surveillance, Epidemiology, and End Results-Medicare database, and propensity score matching was used to match patients who had been… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 23 references

Similar Papers

Loading similar papers…